P vs. CRVS
P (Everpure, Inc.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. P operates in Computer Hardware (Technology), while CRVS operates in Biotechnology (Healthcare). Over the past 10 years, P returned 21.03%/yr vs 0.06%/yr for CRVS. At a 0.21 correlation, their price movements are largely independent.
Performance
P vs. CRVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, P achieves a 7.91% return, which is significantly lower than CRVS's 54.94% return. Over the past 10 years, P has outperformed CRVS with an annualized return of 21.03%, while CRVS has yielded a comparatively lower 0.06% annualized return.
P
- 1D
- 4.28%
- 1M
- -14.36%
- YTD
- 7.91%
- 6M
- 1.39%
- 1Y
- 32.70%
- 3Y*
- 25.48%
- 5Y*
- 30.55%
- 10Y*
- 21.03%
CRVS
- 1D
- 2.84%
- 1M
- -24.68%
- YTD
- 54.94%
- 6M
- 42.53%
- 1Y
- 181.37%
- 3Y*
- 53.32%
- 5Y*
- 33.63%
- 10Y*
- 0.06%
P vs. CRVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
P Everpure, Inc. | 7.91% | 9.08% | 72.27% | 33.26% | -17.79% | 43.96% | 32.14% | 6.41% | 1.39% | 40.23% |
CRVS Corvus Pharmaceuticals, Inc. | 54.94% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 48.23% | -64.58% | -27.55% |
Correlation
The correlation between P and CRVS is 0.10, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.10 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.21 |
Correlation (All Time) Calculated using the full available price history since Mar 23, 2016 | 0.21 |
The correlation between P and CRVS shifts across timeframes, from 0.10 (1 year) to 0.22 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
P:
$23.61B
CRVS:
$1.07B
P:
$0.56
CRVS:
-$0.53
P:
$3.66B
CRVS:
$0.00
P:
$2.58B
CRVS:
-$26.00K
P:
$306.67M
CRVS:
-$47.43M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
P vs. CRVS — Risk / Return Rank
P
CRVS
P vs. CRVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Everpure, Inc. (P) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| P | CRVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.53 | ||
| Sortino ratioReturn per unit of downside risk | -3.13 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.48 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | 0.78 | 3.23 | -2.46 |
| Martin ratioReturn relative to average drawdown | 1.50 | 7.03 | -5.53 |
Loading charts...
Drawdowns
P vs. CRVS - Drawdown Comparison
The maximum P drawdown since its inception was -69.43%, smaller than the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for P and CRVS.
Loading charts...
Drawdown Indicators
| P | CRVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.43% | -96.97% | +27.54% |
Max Drawdown (1Y)Largest decline over 1 year | -42.26% | -56.43% | +14.17% |
Max Drawdown (3Y)Largest decline over 3 years | -48.63% | -70.50% | +21.87% |
Max Drawdown (5Y)Largest decline over 5 years | -48.63% | -92.40% | +43.77% |
Max Drawdown (10Y)Largest decline over 10 years | -69.43% | -96.97% | +27.54% |
Current DrawdownCurrent decline from peak | -26.74% | -53.25% | +26.51% |
Average DrawdownAverage peak-to-trough decline | -24.44% | -69.28% | +44.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.89% | 25.91% | -4.02% |
Volatility
P vs. CRVS - Volatility Comparison
Everpure, Inc. (P) has a higher volatility of 26.95% compared to Corvus Pharmaceuticals, Inc. (CRVS) at 23.12%. This indicates that P's price experiences larger fluctuations and is considered to be riskier than CRVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| P | CRVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.95% | 23.12% | +3.83% |
Volatility (6M)Calculated over the trailing 6-month period | 45.02% | 111.88% | -66.86% |
Volatility (1Y)Calculated over the trailing 1-year period | 68.32% | 180.64% | -112.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 52.74% | 131.02% | -78.28% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 51.15% | 111.13% | -59.98% |
Dividends
P vs. CRVS - Dividend Comparison
Neither P nor CRVS has paid dividends to shareholders.
Financials
P vs. CRVS - Financials Comparison
This section allows you to compare key financial metrics between Everpure, Inc. and Corvus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
P and CRVS have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
P has higher volatility (26.95%) compared to CRVS (23.12%). In terms of maximum drawdown, P dropped -69.43% vs CRVS's -96.97%.
CRVS currently has the higher Sharpe Ratio (1.01 vs 0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for P and CRVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer